Waystar Third Quarter 2026 Earnings Conference Call - WAYSTAR HOLDING CORP

Explicit Guidance:

• Full-Year 2026 Revenue: $1.277 billion to $1.287 billion (midpoint: $1.282 billion); implies Q4 2026 revenue of approx. $323 million and revenue growth of approx. 6%.
• Full-Year 2026 Adjusted EBITDA: $543 million to $549 million (midpoint: $546 million); implies Q4 2026 Adjusted EBITDA of approx. $135 million (approx. 42% margin).
• Full-Year 2026 EBITDA Margin: Approximately 42.5% at the midpoint.
• Full-Year 2026 Capital Expenditures (CapEx): $55 million to $60 million.
• Long-Term Targets: Low double-digit organic revenue growth; Adjusted EBITDA margins of 40% or greater.

Business-Segment Outlook:

• Iodine Integration: Strategic pivot to bundle Clinical Documentation Integrity (CDI) with pre-bill anomaly detection; this performance-based revenue model creates longer implementation-to-revenue conversion periods, resulting in lower 2026 recognition compared to bookings. Iodine bookings exceeded YTD plans by 74% ($30M+ bookings YTD), with a pipeline exceeding $100 million.
• 2027 Iodine Accretion: Management expects Iodine to be accretive in Fiscal Year 2027 despite the 2026 timing drag; pre-bill anomaly detection is seeing the strongest demand and traction, with the majority of future bookings anticipated to follow this outcomes-based pricing model.
• Platform Adoption: Large client cohort (> $100k LTM revenue) now averages five product modules per client (vs. 20+ modules available); implementation backlog for large opportunities grew >50% YoY, with a 2-year CAGR in the mid-30s.
• AI Monetization: Altitude AI-powered offerings comprised ~43% of Q3 bookings; more than 130 clients in early adopter programs. New AI capabilities (including "agentic" features) expected to launch as new SKUs and premium upsell opportunities within existing modules.
• Product Roadmap: Over 20 planned AI capabilities scheduled for the near term to support the "autonomous revenue cycle."

Market and Competitive Outlook:

• Demand Trends: Strong commercial momentum with YTD bookings growth of 25% YoY; large client wins replacing fragmented incumbent vendors (e.g., $7B revenue health system replacing >20 vendors).
• Pricing & Revenue Models: Shift toward performance-based/revenue-share pricing for AI-driven anomaly detection (outcome-based) versus traditional subscription models for CDI; early adopter results show performance metrics aligning with initial estimates.
• Channel Growth: Expansion via strategic partners, particularly in the ambulatory market; new partnership with a physical therapy management system extending reach to ~4,000 providers and ~2,500 sites.
• Outsourcing Market: Outsourced RCM estimated at 15–20% of the total market; AI expected to expand the addressable market by displacing insourced labor rather than solely displacing outsourcing vendors.

Macro / Industry Outlook:

• Revenue Recognition Dynamics: Q4 2026 growth impacted by specific comparison factors: print-to-digital statement shift (lower volumes in Q4), Iodine mix shift to performance-based revenue, and favorable prior-year comparables from three large client implementations.
• Normalization: Absent specific timing factors, Q4 normalized gross rate is estimated at ~10%; Full-year 2026 midpoint implies ~11% normalized organic growth.
• 2027 Outlook: Management anticipates a "cleaner" year-over-year comparison environment in 2027 as 2026-specific comp dynamics roll off. Formal 2027 guidance expected next quarter.

Strategic Initiatives:

• AI & Innovation: Launch of "Altitude AI" agentic capabilities, including autonomous claim resubmission (estimated potential to resubmit up to $5B in rejected claims annually, saving 400k+ hours of manual work).
• Talent Acquisition: Appointment of Amit Khanna as Chief Product and Technology Officer to accelerate AI innovation.
• M&A/Integration: Full integration of Iodine capabilities (clinical intelligence) with Waystar's financial data to enable pre-bill anomaly detection; cross-sell momentum into existing Waystar base contributing $9M in Q3 bookings.
• Capacity/Infrastructure: Network expansion with >100 new payer connections in 2026 (50M transactions annually); total network processing 8.5B+ transactions annually.

Risks and Headwinds to Outlook:

• Implementation Timing: Larger, broader platform deals have longer revenue ramp periods (12–18 months), causing a disconnect between strong bookings (25% YoY) and near-term revenue recognition.
• Mix Shifts: Shift from print to digital patient statements and the transition of Iodine to performance-based pricing models are causing near-term revenue variability and lower Q4 recognition.
• Seasonality: Expectation of seasonally lower patient payment volumes in Q4 due to high-deductible health plan resets.
• Execution Risks: Potential variability in CapEx and execution of AI product launches.

Management Tone on the Future:

• Confidence Level: High confidence in long-term low double-digit growth and 40%+ EBITDA margins; described the current quarter as "strong" and "robust."
• Hedges/Clarification: Management distinguishes between "underlying demand" (strong) and "near-term revenue dynamics" (timing/mix driven).
• Strategic Shift: Emphasis on shifting from volume-based identification to "agents that can execute" work, viewing this as the "big unlock" for the industry.
• Capital Allocation: Maintained discipline with share repurchases ($21M in Q3, $33M YTD) and debt reduction; net leverage at 2.2x.

Miscellaneous:

• Client Metrics: End of Q3 2026 clients >$100k LTM revenue reached 1,488 (up 14% YoY); these clients now represent ~75% of total revenue (up from ~66% two years ago).
• Network Scale: Waystar processes >$3 trillion in gross claims annually and connects ~1.5 million providers.
• Net Revenue Retention (NRR): Held at 108%; management targets 108–110% long-term range, driven by expansion in large client cohorts.
• Cash Flow: Unlevered free cash flow of $115M in Q3; Cash and short-term investments at $277M.